Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity

NCT06259981 is registered in ClinicalTrials.gov with Glyscend, Inc. as lead sponsor.

NCT NCT06259981
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06259981 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity
Lead sponsor
Glyscend, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 20, 2024
Completion date
October 23, 2024
Enrollment
75 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

obesity